Connect with us

News

EU launches initiative to improve reproductive health and rights in Africa

The commitment is part of the EU-Africa Global Gateway package and the EU Global Health Strategy

Published

on

The EU alongside three African regional economic communities have announced a new initiative to improve reproductive health and rights in Africa.

The European and African partners are aiming to improve sexual and reproductive health and rights (SRHR), particularly among adolescent girls and young women, to empower and enable them to reach their full potential.

The initiative, which is hoped to enhance coordination and collaboration among partners, was launched in Kigali, Rwanda on December 15 and is part of the EU-Africa Global Gateway package and the EU Global Health Strategy.

According to the European Commission, the new initiative builds on a joint analysis of gaps, needs, and lessons learnt, and prioritises  areas where a regional perspective can complement global and country level investments, with a focus on increasing the implementation of continental and regional commitments on SRHR in the health and education sector, improving the availability, affordability and acceptability of SRHR goods and strengthening advocacy and accountability.

The pandemic has had a strong negative impact on SRHR in Africa. Reports suggest further action is needed to make available information on SRHR, goods and services and accelerate progress on key issues such as family planning, the fight against gender-based violence, harmful practices, maternal mortality and sexual health and well-being.

“In line with the new EU Global Health Strategy, empowering women, girls and young people by investing in their health and education is key to building prosperous and inclusive societies,” said Commissioner for International Partnerships, Jutta Urpilainen.

“I am proud to launch, as a key follow-up of the AU-EU Summit, this Africa–EU partnership initiative and collaborative framework to advance our shared, strong commitment to realise sexual and reproductive health and rights for all and ensure that we deliver with more impact where it is needed.”

“Together with our European and African partners, we want to make sure that everyone in Sub Saharan Africa, whatever their gender, age or sex, can make their own choices about their body, health and future,” added Frank Vandenbroucke, Deputy Prime Minister and Minister of Social Affairs and Public Health of Belgium, in charge of Development Cooperation and Major Cities Policy.

“With 70 per cent of the region’s population being under the age of 30, it is crucial that younger generations have access to sexual and reproductive health services and information.

“Our expertise and experience in education and health, particularly with regards to Universal Health Coverage, as well as the long-standing cooperation with our African partners are strong assets that will undoubtedly contribute to the SRHR Agenda in Sub Saharan Africa and to establishing universal access to sexual and reproductive health care and rights, especially for young girls and women.”

Birgit Pickel, director general for Africa, German Federal Ministry for Economic Cooperation and Development, said: “Health is a human right. Improving access to reproductive health services has an impact particularly on the lives of women and girls that goes far beyond the health sector.

“Qualitative reproductive health services are thus fundamental to achieving gender equality and to promoting the social, economic, and political participation of women.

Anne-Claire Amprou, Ambassador for Global Health, French Ministry of Europe and Foreign Affairs, stressed that promoting sexual and reproductive health and rights must be a priority.

“It is indeed at the cornerstone of gender equality and human rights, which are also the foundations of our feminist diplomacy.”

Funding from the EU budget includes €60m in new funds for 2023–2027 and EU member states are expected to make new financial commitments in the coming years.

The initiative has been developed by the European Commission, the EU Member States Belgium, Czech Republic, Denmark, Finland, France, Germany, Ireland, Luxemburg, Netherlands and Sweden, and three African regional economic communities: the East African Community (EAC), the West African Health Organization (WAHO) of the Economic Community of West African States (ECOWAS) and the Southern African Development Community (SADC).

The commission says the move will be taken forward in partnership with a range of additional stakeholders, including governments, civil society organisations, private sector, academic institutions and the United Nations.

Diagnosis

Lung cancer drug shows breast cancer potential

Published

on

Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.

PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.

Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.

The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.

In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.

Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.

Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.

Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”

John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”

Continue Reading

Insight

Higher nighttime temps linked to increased risk of autism diagnosis in children – study

Published

on

Nighttime temperatures during pregnancy may be linked to a higher chance of an autism diagnosis in children, a recent study suggests.

The research tracked nearly 295,000 mother-child pairs in Southern California from 2001 to 2014 and linked warmer overnight temperatures with higher risk in early and late pregnancy.

Children of mothers exposed to higher than typical nighttime temperatures during weeks one to 10 of pregnancy had a 15 per cent higher risk of an autism diagnosis.

Exposure during weeks 30 to 37 was linked to a 13 per cent higher risk.

 Lead author David Luglio, a post-doctoral fellow at Tulane University, said: “A key takeaway is that we identified specific windows when a mother and her developing child can be most affected by exposures to higher nighttime temperatures.

“This is critical and hopefully can help mothers prepare accordingly.”

The study is described as the first to examine how temperature may affect fetal neurodevelopment, the process by which a baby’s brain and nervous system form during pregnancy.

Extreme temperatures linked to increased risk were classified as above the 90th percentile, meaning 3.6°F hotter than average, and the 99th percentile, 5.6°F above average.

The association held even after researchers accounted for factors such as neighbourhood conditions, vegetation and fine-particle air pollution.

The study could not account for other factors such as access to air conditioning. Researchers did not find the same association with daytime temperatures, potentially because people spend more time away from home during the day.

“Heat waves are becoming more frequent, and people may only think of the dangers of daytime heat exposure,” said Mostafijur Rahman, assistant professor of environmental health sciences at Tulane University.

“These results indicate a strong association between high nighttime temperatures during pregnancy and autism risk in children and show that we need to think about exposure to heat around the clock.”

The study did not examine how higher temperatures at night might affect prenatal development, though Luglio said it is possible that warmer nights disrupt sleep for pregnant mothers.

Previous research has suggested insufficient sleep during pregnancy may be linked to a higher risk of neurocognitive delays in children.

“Extreme heat exposure during pregnancy has been linked to a range of adverse health outcomes, including prenatal neurodevelopment delays and complications with an embryo’s development of a central nervous system,” Luglio said.

“The goal of our study was to specifically explore the link between prenatal heat exposure and autism diagnoses for the first time.”

Continue Reading

Entrepreneur

Kindbody unveils next-gen fertility platform

Published

on

Kindbody has launched a fertility platform integrating AI with clinical care and patient support for employers and health plans.

The platform will enter a pilot with select Kindbody employer clients in 2026, covering over three million lives, ahead of wider availability in 2027.

Building on the company’s clinical model, the platform aims to improve outcomes and cost efficiency across family-building journeys. It connects Kindbody-owned clinics, partner clinics and an integrated clinical app.

The app offers virtual care across conception, pregnancy and reproductive health, extending through the menopause transition.

Launch features include updates in medication management, third-party reproduction, adoption, pregnancy, men’s health and global programme design.

David Stern, chief executive of Kindbody, said: “With our next-generation fertility platform, Kindbody is redefining what comprehensive, intelligent and affordable family-building care looks like for employers, health plans and patients.

“By unifying best-in-class clinical care, AI-driven intelligence and whole-person support, we are making it easier and more cost-effective for more people to build the families they envision.”

Kindbody has expanded access via its national network of IVF centres, including IVIRMA, Inception Fertility and Ivy Fertility.

A new Fertility Medication Portal is designed to streamline authorisations so medicines can be dispensed on time, giving patients visibility from prescription to coverage, pharmacy fulfilment and delivery tracking.

Through KindMan, men’s health education, digital resources and integrated clinical care are expanding, including hormone management programmes.

Services cover andropause (age-related testosterone decline), erectile dysfunction, low testosterone and other male reproductive conditions.

Specialist fertility care includes semen analysis, diagnostic testing, male hormone panels, genetic testing, surgical sperm extraction and sperm cryopreservation.

Launching in the second quarter, a pregnancy support app will act as a digital companion for expecting and new parents, with resources, interactive tools and clinical assessments to identify social drivers of health and mental health needs during pregnancy and beyond.

Kindbody’s physician-led menopause programme provides consultations with board-certified obstetricians and gynaecologists to diagnose, treat and manage menopausal symptoms, including hormone replacement therapy where appropriate, with support from nutritionists, mental health therapists and pelvic floor specialists.

AI and analytics will be embedded across the care journey. An AI care navigator will guide employees from benefit activation through intake, triage and scheduling.

Tools will track benefits and treatment plans, showing coverage and expected out-of-pocket costs at each step.

AI-supported scribing will assist clinicians with documentation, and a predictor tool will estimate a patient’s likelihood of having a baby across different treatment paths.

In 2027, Kindbody plans a savings model for eligible large employers that it says will guarantee lower total fertility spend while improving clinical efficiency and patient experience.

Continue Reading

Trending

Copyright © 2025 Aspect Health Media Ltd. All Rights Reserved.